Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eliapixant in Healthy Volunteers and Refractory Chronic Cough
NCT03310645Phase 2Completed
- Sponsor
- Bayer
- Start
- Dec 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eliapixant in refractory chronic cough (RCC), sponsored by Bayer. Started Dec 2017; status: completed.
02
Drugs
eliapixant
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on NCT03310645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03310645.